Emergent Biosolutions (NYSE:EBS) : 2 Wall Street analysts covering Emergent Biosolutions (NYSE:EBS) believe that the average level the stock could reach for the short term is $43.5. The maximum price target given is $47 and the minimum target for short term is around $40, hence the standard deviation is calculated at $4.95.
Other Equity analysts have also commented on the company shares. Chardan Capital initiates coverage on Emergent Biosolutions (NYSE:EBS). The current rating of the shares is Buy, according to the research report released by the firm. The brokerage firm announces the price target at $47 per share. The rating by the firm was issued on April 15, 2016.
Emergent Biosolutions (NYSE:EBS): On Thursdays trading session , Opening price of the stock was $31.39 with an intraday high of $32.13. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $29.895. However, the stock managed to close at $30.65, a loss of 2.17% for the day. On the previous day, the stock had closed at $31.33. The total traded volume of the day was 2,695,869 shares.
The company shares have dropped -4.80% from its 1 Year high price. On Jun 7, 2016, the shares registered one year high at $44.38 and the one year low was seen on Oct 7, 2015. The 50-Day Moving Average price is $41.07 and the 200 Day Moving Average price is recorded at $37.79. On the companys insider trading activities, The Securities and Exchange Commission has divulged that Joulwan George A, director of Emergent Biosolutions Inc., had unloaded 4,700 shares at an average price of $44.12 in a transaction dated on June 6, 2016. The total value of the transaction was worth $207,364.
Emergent BioSolutions Inc. is a biopharmaceutical company that offers specialized products to healthcare providers and Governments to address medical needs and emerging health threats. The Companys two operating divisions include Biodefense and Biosciences. The Companys Biodefense division is a pharmaceutical business focused on countermeasures that address CBRNE (Chemical, Biological, Radiological, Nuclear and Explosives) threats. The Biodefense divisions marketed products are BioThrax; BAT; Anthrasil; VIGIV, and RSDL. The Biodefense division investigational stage product candidates include NuThrax, PreviThrax, GC-072 and other biodefense product candidates. The Biosciences divisions marketed products are WinRho SDF, HepaGam B, VARIZIG and episil. The Biosciences division investigational stage product candidates include IXINITY, ES414 and otlertuzumab.